好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence and Significance of Multiple Hypercoagulable Conditions in Cerebral Venous Thrombosis: 12 years of Experience in a Referral Center
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
5-026

We aimed to calculate the prevalence of different hypercoagulable conditions in our sample of patients with CVT and to determine the clinical and laboratory predictors of CVT severity.
Cerebral vein thrombosis (CVT) is a rare manifestation of venous thromboembolism (VTE) with a highly variable presentation and clinical course with mortality rate ranges between 2% - 8%. The relationship between CVT severity and hypercoagulable states is not fully understood and has never been studied before.

We retrospectively reviewed confirmed CVT cases among adults hospitalized in our institution between 2009 and 2021. We calculated the prevalence of the following hypercoagulable factors: antiphospholipid syndrome, factor VII, VIII, and XI, protein C and S deficiency, APC resistance, factor V Leiden, antithrombin deficiency, prothrombin mutation, MTHFR mutation, lipoprotein-a, and sickle cell disease. We used logistic regression to analyze the association between different variables and CVT severity (defined as ICU stay or being discharged to nursing home or long-term care, or death).
184 patients were found, mean age 43.9, 56.0% women, and 74.5% white. 102 patients (55.4%) required ICU care, 148 (80.43%) had good discharge destinations (home or rehab), and 17 patients (9.2%) died. Head trauma was the most prevalent comorbidity (47 cases, 25.5%), followed by recent craniectomy (22 cases, 12.0%). Hypercoagulable profile was sent in 75 cases (40.8%) among which, 89.3% has at least one abnormal lab. There was an association between CVT severity and the presence of any comorbidity. No statistical evidence of any correlation between any of the hypercoagulable conditions and CVT severity. 
Hypercoagulable conditions do NOT predict CVT severity. However, they remain an important tool to establish the etiology of CVT and to determine the length of treatment.
Authors/Disclosures
Ahmad Al-Awwad, MD (University of Oklahoma)
PRESENTER 		Dr. Al-Awwad has nothing to disclose.
Ahmer Asif, MD Dr. Asif has nothing to disclose.
David L. Gordon, MD, FAHA, FANA, FAAN (University of Oklahoma HSC) Dr. Gordon has nothing to disclose.
Linda A. Hershey, MD, PhD, FAAN Dr. Hershey has received personal compensation for serving as an employee of 好色先生. Dr. Hershey has received personal compensation for serving as an employee of MedLink Neurology LLC. Dr. Hershey has received personal compensation for serving as an employee of American College of Physicians. Dr. Hershey has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. An immediate family member of Dr. Hershey has stock in Diverse portfolio.
Veronica A. Moreno Gomez, MD (Department of Neurology) Dr. Moreno Gomez has nothing to disclose.
Zainab Al Obaidi, MD (University of Oklahoma Health Sciences Center) Dr. Al Obaidi has nothing to disclose.
Chao Xu Chao Xu has nothing to disclose.
Calin I. Prodan, MD (Univ of Oklahoma - Neurology Dept) The institution of Dr. Prodan has received research support from US Department of Veterans Affairs (Merit award CX000340).